Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04146051
Recruitment Status : Recruiting
First Posted : October 31, 2019
Last Update Posted : May 19, 2023
Sponsor:
Information provided by (Responsible Party):
Cartesian Therapeutics

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

Condition or disease Intervention/treatment Phase
Myasthenia Gravis, Generalized Drug: Descartes-08 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG)
Actual Study Start Date : December 4, 2019
Estimated Primary Completion Date : December 1, 2023
Estimated Study Completion Date : December 1, 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Phase 1b Dose-Escalation
Generalized Myasthenia Gravis
 Drug: Descartes-08
Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
Experimental: Phase IIa Expansion
Generalized Myasthenia Gravis
 Drug: Descartes-08
Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
Placebo Comparator: Phase IIb Randomized Control Trial
Generalized Myasthenia Gravis
 Drug: Descartes-08
Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Myasthenia Gravis -Activities of Daily Living Score [ Time Frame: Day 0 to Day 85 ]
    In Part 3, the primary objective is to compare the effect of Descartes-08 versus placebo, as measured by the change in MG ADL score from baseline to Week 12. In Part 1, up to three ascending doses of Descartes-08 will be administered to each of 3 to 6 patients; the patients will be staggered at least 21 days apart and will complete a safety review between each dose. In Part 2, patients will receive up to 6 doses in three different schedules depending on the arm they were enrolled into and will be monitored for up to 1 year to assess the safety and tolerability of a repeated dosing schedule.


Secondary Outcome Measures :
  1. Comparison on Descartes-08 versus placebo on QMG, MG QoL 15R, MG Composite, MG PIS [ Time Frame: Day 0 to Day 85 ]
    Compare the effect of Descartes-08 versus placebo on QMG, MG QoL 15R, MG Composite, and MG PIS (change from baseline to Week 12) for all randomized patients (Part 3 only).

  2. Comparison on Descartes-08 versus placebo on MG assessments in crossover patients [ Time Frame: Day 0 to Day 85 ]
    Compare the effect of Descartes-08 versus placebo on MG ADL, QMG, MG QoL 15R, MG Composite, and MG PIS (change from baseline to Week 12) in patients who cross over from placebo to Descartes-08 (Part 3 only).

  3. Change in titer of myasthenia specific autoantibody titers [ Time Frame: Day 0 to Day 168 ]
    Determine the change from baseline over a period of 24 weeks in the titer of myasthenia specific autoantibody titers, e.g. nicotinic acetylcholine receptor autoantibody (anti-nAChR) or muscle-specific tyrosine kinase autoantibody (anti- MusK or anti-Low-Density-Lipoprotein-Related-Protein4 (anti-LRP4) or anti-AChR cluster antibody and the 4 Immunoglobulin types (IgG, IgM, IgA, IgE) following single or multiple infusions of Descartes-08 in MG auto-antibody seropositive patients (Parts 1 and 2 only)

  4. Effect of single or multiple infusions of Descartes-08 on patients by standard clinical assessment scales [ Time Frame: Day 0 to Day 168 ]
    Quantify the clinical effect of single or multiple infusions of Descartes-08 on patients by standard clinical assessment scales (MG ADL, QMG, MG QoL 15R, MG PIS, MG Composite) over a period of 24 weeks in MG auto-antibody seropositive and seronegative patients together and separately (all parts).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient must be at least 18 years of age.
  • Patient must have Generalized Myasthenia Gravis at the time of screening.
  • Concomitant immunosuppressive drugs must be deemed necessary by the investigator.
  • Seronegative Patients are included

Exclusion Criteria:

  • Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient.
  • Patient is pregnant or lactating.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04146051


Contacts
Layout table for location contacts
Contact: Study Trial Central Mailbox 302-648-6497 trials@cartesiantx.com

Locations
Layout table for location information
United States, California
The Research Center of Southern California Recruiting
Carlsbad, California, United States, 92011
Principal Investigator: Gregory Sahagian, MD         
University of California Irvine Recruiting
Irvine, California, United States, 92697
Principal Investigator: Tahseen Mozaffar, MD         
United States, Colorado
University of Colorado Anschutz Medical Campus Recruiting
Aurora, Colorado, United States, 80045
Contact: Brianna Blume         
Principal Investigator: Thomas Ragole, M.D.         
United States, Florida
SFM Clinical Research, LLC Recruiting
Boca Raton, Florida, United States, 33487
Principal Investigator: Marc Feinberg, MD         
Neurology Associates, P.A. Recruiting
Orlando, Florida, United States, 32751
Principal Investigator: Adam Slansky, MD         
University of South Florida Recruiting
Tampa, Florida, United States, 33612
Principal Investigator: Tuan H. Vu, MD         
United States, Georgia
University of Augusta Recruiting
Augusta, Georgia, United States, 30912
Principal Investigator: Michael Rivner, MD         
United States, Kansas
University of Kansas Medical Center Research Institute Recruiting
Kansas City, Kansas, United States, 66160
Contact: Ali Ciersdorff         
Contact: Andrew Heim         
Principal Investigator: Mamatha Pasnoor, M.D.         
United States, New York
Dent Neurologic Institute Recruiting
Amherst, New York, United States, 14226
Principal Investigator: Bennett Myers, MD         
United States, North Carolina
University of North Carolina Recruiting
Chapel Hill, North Carolina, United States, 27599
Principal Investigator: James F Howard, MD         
United States, Oregon
Oregon Health & Science University Recruiting
Portland, Oregon, United States, 97239
Principal Investigator: Nizar Chahin, MD         
United States, Pennsylvania
University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Kelsey Moulton         
Contact: Sara-Claude Michon, Ph.D.         
Principal Investigator: Chafic Karam, M.D.         
Alleghany Health Network Recruiting
Pittsburgh, Pennsylvania, United States, 15212
Contact: Dom Contestabile         
Principal Investigator: George Small, M.D.         
United States, Virginia
Virginia Commonwealth University Recruiting
Richmond, Virginia, United States, 23219
Contact: Melissa Hayes         
Principal Investigator: Kelly Gwathmey, M.D.         
Canada, Alberta
University of Alberta Recruiting
Edmonton, Alberta, Canada, T6G2C8
Contact: Faraz Hussain, Ph.D.         
Principal Investigator: Zaeem Siddiqi, M.D.         
Sponsors and Collaborators
Cartesian Therapeutics
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Cartesian Therapeutics
ClinicalTrials.gov Identifier: NCT04146051    
Other Study ID Numbers: MG-001
First Posted: October 31, 2019    Key Record Dates
Last Update Posted: May 19, 2023
Last Verified: May 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Cartesian Therapeutics:
Descartes-08
CART
CAR-T
Autoimmune
Auto-antibody
Auto antibody
 chimeric antigen receptor
T cells
MG
gMG
Myasthenia Gravis
Generalized Myasthenia gravis
Additional relevant MeSH terms:
Layout table for MeSH terms
Myasthenia Gravis
Muscle Weakness
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Pathologic Processes
Paraneoplastic Syndromes, Nervous System
Nervous System Neoplasms
 Neoplasms by Site
Neoplasms
Paraneoplastic Syndromes
Autoimmune Diseases of the Nervous System
Neurodegenerative Diseases
Neuromuscular Junction Diseases
Neuromuscular Diseases
Autoimmune Diseases
Immune System Diseases